ISRG posts 20% Q3 procedure growth as da Vinci and Ion volumes accelerate, but investors question if product cycles and timing effects can sustain it.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $572.47, indicating a +1.88% shift from the previous trading day.
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Intuitive Surgical broadens its da Vinci SP system with FDA clearance for three new surgeries, expanding its role in minimally invasive care.
Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $566.89, signifying a -1.47% move from its prior day's close.
Intuitive Surgical's golden crossover arrives amid surging procedures and rapid dV5 adoption, raising the stakes for its bullish momentum.
Intuitive Surgical (ISRG) stock may represent a worthwhile investment at present. Why? Because you receive high margins – indicative of pricing power and cash generation capability – at a discounted price.
Intuitive Surgical (ISRG) stock may represent a worthwhile investment at present. Why? Because you receive high margins – indicative of pricing power and cash generation capability – at a discounted price.
Intuitive Surgical's strong growth contrasts with tariff-driven margin pressure, raising questions about its ability to hold gross margins near 67%.
In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $567.37, denoting a -1.07% move from the preceding trading day.